S-1/A: Zeo ScientifiX Files Amendment No. 1 to Form S-1 Registration Statement for Resale of 4,426,823 Shares of Common Stock

Zeo ScientifiX has filed an amendment to its S-1 registration statement, covering the proposed resale of up to 4,426,823 shares of its common stock by selling stockholders.

Summary

• Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, has filed Amendment No. 1 to its Form S-1 registration statement.
• The filing pertains to the proposed resale of up to 4,426,823 shares of common stock by selling stockholders.
• These shares were acquired or are issuable upon conversion or exercise of securities acquired by the selling stockholders in exempt transactions.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders, but will receive the exercise price of warrants if they are exercised for cash.
• The common stock is currently quoted on the OTCQB under the symbol ZEOX, with a closing price of $2.28 on May 15, 2025.
• The prospectus outlines various risk factors associated with investing in the company's common stock.
• The company is pursuing efforts to complete its already approved clinical studies as well as obtaining approval to commence additional studies for other specific indications.
• The company is undertaking efforts on an ongoing basis to mitigate any potential risks associated with an adverse ruling by the FDA and the subsequent limitations on our ability to continue to generate revenues from the sale of our products in the United States until the Company obtains the required licenses.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as ongoing clinical trials and efforts to mitigate regulatory risks, the company's financial struggles and the high risks associated with the stock offering contribute to a negative outlook.

Positives

• The company is pursuing efforts to complete its already approved clinical studies as well as obtaining approval to commence additional studies for other specific indications.
• The company is undertaking efforts on an ongoing basis to mitigate any potential risks associated with an adverse ruling by the FDA and the subsequent limitations on our ability to continue to generate revenues from the sale of our products in the United States until the Company obtains the required licenses.

Negatives

• The company will not receive any proceeds from the sale of shares by selling stockholders, except if warrants are exercised.
• The purchase of the shares of common stock offered through this prospectus involves a high degree of risk.
• The company has incurred significant losses, has limited cash on hand and there is substantial doubt as to our ability to continue as a going concern.

Risks

• The prospectus highlights a high degree of risk associated with purchasing the common stock.
• The company has incurred significant losses and has limited cash on hand, raising substantial doubt about its ability to continue as a going concern.
• The company's success depends on the availability of sufficient quantities of tissue from human donors, and any disruption in supply could adversely affect our business.
• The company is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and our failure to comply could result in negative effects on our business.

Future Outlook

The company is pursuing efforts to complete its already approved clinical studies as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available.

Industry Context

The company operates in the regenerative medicine industry, which is characterized by intense competition, rapid technological change, and evolving regulatory landscape. The company is pursuing efforts to complete its already approved clinical studies as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available.

Comparison to Industry Standards

• The regenerative medicine field is highly competitive and subject to rapid technological change and regulation.
• Companies compete on the basis of regulatory compliance, product efficacy, pricing, and ease of handling/logistics.
• A critically important factor for growth in the US market is third-party reimbursement, which is difficult to obtain, and the process can be time-consuming and expensive.
• We expect that it will take some time before RAAM products will be widely accepted under health insurance coverage.

Legal Proceedings

• On November 19, 2024, Howard Golub, M.D., the Companys former Chief Science Officer, filed a complaint against the Company, alleging a breach of contract as a result of the Companys failure to pay him severance in the amount of $150,000 in connection with the non-renewal of Dr. Golubs employment agreement with the Company.

Related Party Transactions

• For the years ended October 31, 2024 and 2023, the Company sold a total of approximately $199,000 and $181,000 of product to a management services organization (MSO) that provides administrative services and contracts for medical supplies for several medical practices, of which Dr. George Shapiro, the Companys Chief Medical Officer and a member of the board of directors has an indirect economic interest in the parent company that owns the MSO.

Stakeholder Impact

• The offering involves a high degree of risk for investors, who could lose their entire investment.
• The company's ability to continue as a going concern is uncertain, which could impact employees, suppliers, and other stakeholders.

Next Steps

• The selling stockholders will determine when and how they will sell the shares of common stock offered in this prospectus.

Key Dates

Keywords

common stock, resale, registration statement, warrants, Zeo ScientifiX, shares, stockholders, biopharmaceutical, FDA, clinical trials